In patients with diabetic macular edema, small gauge pars plana vitrectomy should be considered as a first-line treatment, ...

Key market opportunities for Lucentis include its broad approval for multiple retinal diseases, its proven clinical efficacy, and strong physician trust. Despite competition, its established global ...

RA tirzepatide for type 2 diabetes mellitus (T2DM) therapy has lower odds of instigating retinal complications.

Pregnancy-related vision changes: find out from an expert why vision changes may occur and how the bodily changes during pregnancy affect your vision.

ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.

When managing vitreous floaters, ophthalmologists must remember that some may masquerade as surgical disease, and that not ...

EyePoint said on Thursday an independent safety committee found no new concerns in ​two late-stage trials of its experimental eye disease drug ‌Duravyu and recommended the studies continue unchanged.

Curacle licenses retinal antibody MT-103 to US Memento in $1.08b deal Memento gains exclusive global rights to MT-103 as ...

DURAVYU has established safety and efficacy data from both Phase 1 and 2 trials in wet AMD and DME that demonstrate stability in vision and anatomical control with a single dose of DURAVYU. No ...

Purpose The cross-sectional and longitudinal associations between accelerated biological ageing and the risk of cataract and ...

NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to ...

Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026Licaminlimab PREDICT-1 Trial in Active Site ...